Selective Elimination of Amplified CDK4 Sequences Correlates with Spontaneous Adipocytic Differentiation in Liposarcoma

被引:28
|
作者
Helias-Rodzewicz, Zofia [1 ,2 ]
Pedeutour, Florence [3 ,4 ]
Coindre, Jean-Michel [5 ]
Terrier, Philippe [6 ]
Aurias, Alain [1 ,2 ]
机构
[1] Inst Curie Genet & Biol Canc, F-75248 Paris 05, France
[2] INSERM U830, F-75248 Paris 05, France
[3] Nice Univ Hosp, Lab Solid Tumors Genet, F-06107 Nice, France
[4] Fac Med Nice, CNRS UMR 6543, F-06107 Nice, France
[5] Inst Bergonie, Dept Pathol, F-33076 Bordeaux, France
[6] Inst Gustave Roussy, Dept Pathol, F-94805 Villejuif, France
来源
GENES CHROMOSOMES & CANCER | 2009年 / 48卷 / 11期
关键词
SOFT-TISSUE TUMORS; SUPERNUMERARY RING CHROMOSOMES; DOUBLE-MINUTE CHROMOSOMES; LIPOMATOUS TUMORS; X-CHROMOSOME; DEDIFFERENTIATED LIPOSARCOMAS; CYTOGENETIC FINDINGS; MYC GENES; C-MYC; CELLS;
D O I
10.1002/gcc.20696
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Well-differentiated and undifferentiated liposarcomas are characterized by high-level amplifications of chromosome 12 regions including the CDK4 and MDM2 genes. These amplicons are either localized, in well-differentiated liposarcoma (WDLPS), on extrachromosomal structures (ring or rod chromosomes), or integrated into chromosome arms in undifferentiated tumors. Our results reveal that extrachromosomal amplicons are unstable, and frequently lost by micronucleation. This loss correlates with hypermethylation of eliminated sequences and changes of their replication time. Treatment of cells with demethylating agents during early S-phase significantly decreases the rate of micronuclei positive for CDK4. We also demonstrate that, in our model, micronuclei are generated during anaphase as a consequence of anaphase abnormalities (chromosome lagging and anaphase bridges). Finally, a dramatic increase of adipocytic differentiation was noted in cells that have eliminated copies of CDK4 gene in micronuclei. These findings provide evidence that, in WDLPS, adipocytic differentiation could be the consequence of CDK4 loss, an event occurring rarely in undifferentiated tumors in which the amplified sequences are integrated into chromosome arms. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码:943 / 952
页数:10
相关论文
共 50 条
  • [1] Phase II trial of the CDK4 inhibitor PD0332991 in CDK4-amplified liposarcoma
    Dickson, Mark Andrew
    Keohan, Mary Louise
    Tap, William D.
    Antonescu, Cristina
    Landa, Jonathan
    Qin, Li-Xuan
    Dohrenwend, Eric Gerard
    Rathbone, Dustin
    Ustoyev, Yelena
    Condy, Mercedes M.
    Singer, Samuel
    Schwartz, Gary K.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo
    Zhang, Yi-Xiang
    Sicinska, Ewa
    Czaplinski, Jeffrey T.
    Remillard, Stephen P.
    Moss, Samuel
    Wang, Yuchuan
    Brain, Christopher
    Loo, Alice
    Snyder, Eric L.
    Demetri, George D.
    Kim, Sunkyu
    Kung, Andrew L.
    Wagner, Andrew J.
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (09) : 2184 - 2193
  • [3] Dissecting the role of CDK4 in liposarcoma
    Vanni, Silvia
    Gallo, Graziana
    Fausti, Valentina
    Miserocchi, Giacomo
    Liverani, Chiara
    Spadazzi, Chiara
    Cocchi, Claudia
    Calabrese, Chiara
    De Luca, Giovanni
    Bassi, Massimo
    Gessaroli, Manlio
    Campobassi, Angelo
    Pieri, Federica
    Ercolani, Giorgio
    Cavaliere, Davide
    Gurrieri, Lorena
    Riva, Nada
    Martinelli, Giovanni
    Mercatali, Laura
    De Vita, Alessandro
    CANCER RESEARCH, 2023, 83 (07)
  • [4] Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified liposarcoma.
    Dickson, Mark Andrew
    Tap, William D.
    Keohan, Mary Louise
    D'Angelo, Sandra P.
    Gounder, Mrinal M.
    Chi, Ping
    Antonescu, Cristina R.
    Landa, Jonathan
    Qin, Li-Xuan
    Rathbone, Dustin D.
    Ustoyev, Yelena
    Crago, Aimee Marie
    Singer, Samuel
    Schwartz, Gary K.
    Condy, Mercedes M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma
    Dickson, Mark A.
    Tap, William D.
    Keohan, Mary Louise
    D'Angelo, Sandra P.
    Gounder, Mrinal M.
    Antonescu, Cristina R.
    Landa, Jonathan
    Qin, Li-Xuan
    Rathbone, Dustin D.
    Condy, Mercedes M.
    Ustoyev, Yelena
    Crago, Aimee M.
    Singer, Samuel
    Schwartz, Gary K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (16) : 2024 - +
  • [6] CDK4 Amplification Predicts Recurrence of Well-Differentiated Liposarcoma of the Abdomen
    Lee, Sanghoon
    Park, Hyojun
    Ha, Sang Yun
    Paik, Kwang Yeol
    Lee, Seung Eun
    Kim, Jong Man
    Park, Jae Berm
    Kwon, Choon Hyuck David
    Joh, Jae-Won
    Choi, Yoon-La
    Kim, Sung Joo
    PLOS ONE, 2014, 9 (08):
  • [7] Separate amplified regions encompassing CDK4 and MDMZ in human sarcomas
    Berner, JM
    Forus, A
    Elkahloun, A
    Meltzer, PS
    Fodstad, O
    Myklebost, O
    GENES CHROMOSOMES & CANCER, 1996, 17 (04): : 254 - 259
  • [8] Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma.
    Dickson, Mark Andrew
    Koff, Andrew
    D'Angelo, Sandra P.
    Gounder, Mrinal M.
    Keohan, Mary Louise
    Kelly, Ciara Marie
    Chi, Ping
    Antonescu, Cristina R.
    Landa, Jonathan
    Qin, Li-Xuan
    Crago, Aimee Marie
    Singer, Samuel
    Tap, William D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Treating cancer with selective CDK4/6 inhibitors
    Ben O'Leary
    Richard S. Finn
    Nicholas C. Turner
    Nature Reviews Clinical Oncology, 2016, 13 : 417 - 430
  • [10] How selective are clinical CDK4/6 inhibitors?
    Hendrychova, Denisa
    Jorda, Radek
    Krystof, Vladimir
    MEDICINAL RESEARCH REVIEWS, 2021, 41 (03) : 1578 - 1598